利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

76 条记录 (耗时 0.037 秒)

    MOBILE TERMINAL AND COMMUNICATION HISTORY PROVIDING METHOD USING THE SAME
    45.
    发明申请
    MOBILE TERMINAL AND COMMUNICATION HISTORY PROVIDING METHOD USING THE SAME 有权
    移动终端和通信历史提供方法

    公开(公告)号：US20100075637A1

    公开(公告)日：2010-03-25

    申请号：US12427235

    申请日：2009-04-21

    申请人： Kyung Jin Kim ,  Jee Young Chun ,  Sae Kyu Park ,  Yong Man Park ,  Ji Hyun Kim

    发明人： Kyung Jin Kim ,  Jee Young Chun ,  Sae Kyu Park ,  Yong Man Park ,  Ji Hyun Kim

    IPC分类号： H04L12/58

    CPC分类号： H04L51/34 ,  H04L51/38

    摘要： A mobile terminal including a communication unit configured to provide a communication function including at least one of an outgoing communication function and an incoming communication function, a controller configured to acquire surrounding data including at least one of image data or sound data corresponding to a surrounding of where the communication function is performed, and to match the acquired surrounding data with communication information indicating a first party of the outgoing function or a second party of the incoming communication function, and a display unit configured to display a communication history including the communication information matched with the surrounding data. In addition, the controller is further configured to acquire the surrounding data selectively based on a) a manual operation of the terminal or b) automatically without user intervention.

    摘要翻译： 一种移动终端，包括：通信单元，被配置为提供包括传出通信功能和传入通信功能中的至少一个的通信功能;控制器，被配置为获取周围数据，所述控制器被配置为获取包括与周围环境对应的图像数据或声音数据中的至少一个 其中执行通信功能，并且将获取的周围数据与指示出站功能的第一方的通信信息或进入通信功能的第二方匹配;以及显示单元，被配置为显示包括匹配的通信信息的通信历史 与周围的数据。 此外，控制器还被配置为基于a）终端的手动操作或b）自动地获取周围数据而无需用户干预。

    METHODS OF TREATING DISEASES WITH ANTI-VEGF ANTIBODIES
    47.
    发明申请
    METHODS OF TREATING DISEASES WITH ANTI-VEGF ANTIBODIES 审中-公开
    用抗VEGF抗体治疗疾病的方法

    公开(公告)号：US20090081232A1

    公开(公告)日：2009-03-26

    申请号：US12329428

    申请日：2008-12-05

    申请人： Kyung Jin Kim

    发明人： Kyung Jin Kim

    IPC分类号： A61K39/395 ,  A61P35/00

    CPC分类号： C07K16/22 ,  A61K38/00 ,  A61K47/6425 ,  A61K47/6811 ,  A61K47/6843 ,  A61K2039/505 ,  C07K14/52 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/30

    摘要： The present invention provides monoclonal antibodies, and portions thereof, which are capable of specifically binding to human vascular endothelial cell growth factor (hVEGF) or hVEGF-related protein. The invention also provides hybridoma cell lines that produce such monoclonal antibodies. The monoclonal antibodies of the invention are useful as therapeutic agents either by themselves or in conjunction with cytotoxic or other chemotherapeutic agents, to treat diseases that are characterized by excessive vascular endothelial cell proliferation. The monoclonal antibodies of the invention also are useful in diagnostic and analytical methods for determining the presence of hVEGF or hVEGF related-protein in a test sample.

    摘要翻译： 本发明提供能够特异性结合人血管内皮细胞生长因子（hVEGF）或hVEGF相关蛋白的单克隆抗体及其部分。 本发明还提供了产生这种单克隆抗体的杂交瘤细胞系。 本发明的单克隆抗体本身或与细胞毒性或其它化学治疗剂联用可用作治疗剂，以治疗以过量血管内皮细胞增殖为特征的疾病。 本发明的单克隆抗体也可用于测定样品中hVEGF或hVEGF相关蛋白的存在的诊断和分析方法。

    Monoclonal antibodies to human leukemia inhibitory factor
    48.
    发明授权
    Monoclonal antibodies to human leukemia inhibitory factor 失效
    人白血病抑制因子单克隆抗体

    公开(公告)号：US5688681A

    公开(公告)日：1997-11-18

    申请号：US258918

    申请日：1994-06-13

    申请人： Kyung Jin Kim

    发明人： Kyung Jin Kim

    IPC分类号： A61K38/00 ,  C07K16/24 ,  C12P21/08 ,  C12N5/20 ,  G01N33/53

    CPC分类号： C07K16/244 ,  A61K38/00 ,  C07K2317/74

    摘要： The invention relates to monoclonal antibodies to human leukemia inhibitory factor. The disclosed monoclonal antibodies are believed to recognize unique epitopes on hLIF and are useful in the treatment of conditions wherein the presence of hLIF causes or contributes to undesirable pathological effects, such as cachexia, dysregulated calcium metabolism, or excessive bone cell proliferation, and in the detection of hLIF, for example, in clinical samples or specimens.

    摘要翻译： 本发明涉及人白血病抑制因子的单克隆抗体。 所公开的单克隆抗体被认为在hLIF上识别出独特的表位，并且可用于治疗其中hLIF的存在引起或有助于不期望的病理学作用，例如恶病质，调节钙代谢或过度骨细胞增殖的病症，并且在 检测hLIF，例如临床样本或标本。